With this link and the known crosstalk between the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway and MAPK pathway, the assessment of BRAF and KRAS mutational status as molecular biomarker for the survival benefit associated with the use of aspirin could be a next step to unravel the biological effect of aspirin in colon cancer [17]. This evidence concerns the gene KRAS and malignant colon neoplasm.